Champions Oncology (CSBR) Liabilities and Shareholders Equity (2011 - 2026)

Champions Oncology (CSBR) has 16 years of Liabilities and Shareholders Equity data on file, last reported at $33.3 million in Q3 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 8.98% year-over-year to $33.3 million in Q3 2026; TTM through Jul 2026 was $118.9 million, a 0.11% change from a year earlier, with the FY2026 full-year figure at $27.0 million, down 16.56% from the prior year.
• Liabilities and Shareholders Equity for Q3 2026 stood at $33.3 million, up from $27.0 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $36.4 million in Q4 2022 and bottomed at $24.9 million in Q3 2024.
• Historically, Liabilities and Shareholders Equity has averaged $30.7 million across 5 years, with a median of $30.5 million in 2025.
• The widest annual swing landed in 2022, when Liabilities and Shareholders Equity soared 32.95%; it then dropped 25.9% in 2024.
• Year by year, Liabilities and Shareholders Equity stood at $36.4 million in 2022, then retreated by 22.19% to $28.3 million in 2023, then declined by 10.79% to $25.2 million in 2024, then advanced by 19.5% to $30.2 million in 2025, then climbed by 10.37% to $33.3 million in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $33.3 million in Q3 2026, $27.0 million in Q2 2026, and $28.4 million in Q1 2026.